On December 1, 2025, the Centers for Medicare & Medicaid Services (CMS) Innovation Center announced its latest model鈥 (Advancing Chronic Care with Effective, Scalable Solutions). A national, voluntary 10-year model designed to test outcomes-focused payment for technology-enabled care used in managing chronic conditions common among Original Medicare (fee-for-service) beneficiaries, ACCESS addresses the long-standing gap between Medicare鈥檚 payment system and technology鈥檚 capacity to improve healthcare delivery.
The digital health technology and provider communities have expressed considerable interest in ACCESS. The US Department of Health and Human Services (HHS) and CMS highlighted the model at the December 4, 2025, Modernizing America鈥檚 Care for the Better event (recording here), noting over 250 organizations have already expressed interest in the model. Nonetheless, many details need clarification before the program launches.
红领巾瓜报 (红领巾瓜报) has reviewed the ACCESS model and is engaging with those agencies and organizations working on design and implementation. In this article, we share early insights and considerations for Medicare organizations and technology manufacturers interested in participating, as well as potential implications for the broader market.
Model Overview
ACCESS aligns with the administration鈥檚 strategic priorities for the Innovation Center, including:
- Incentivize greater use of聽technology聽in聽chronic聽disease prevention and management聽
- Increase access to聽tech-enabled care聽by overcoming聽payment聽barriers, while ensuring care is clinician-guided, coordinated, and accountable聽
- Expand聽clinicians鈥櫬燼bility to offer innovative care through聽a聽straightforward payment pathway聽
- Promote competition by publishing risk-adjusted performance results聽
- Reduce overall Medicare costs聽
Core Requirements for ACCESS Participants
Participants in the model (ACCESS care organizations) must be Medicare Part B participating providers or suppliers, exclusive of durable medical equipment, prosthetics, orthotics, and laboratory suppliers. Notably, these organizations must designate a Medicare-enrolled medical director to oversee care quality and compliance. These organizations will collaborate with primary care providers and other referring clinicians to offer tech-enabled services that complement traditional care, including:
- Telehealth software聽
- Wearable devices for continuous monitoring (e.g., sleep, heart rate, movement, glucose, etc.)聽
- Apps聽to聽track and coach lifestyle changes聽
Care may be delivered in person, virtually, asynchronously, or through other clinically appropriate tech-enabled methods.
While CMS has yet to release full details on covered digital health solutions, ACCESS care organizations are expected to offer integrated, technology-supported care, which may include:
- Clinician consultations聽
- Lifestyle and behavioral support (e.g., nutrition, exercise, smoking cessation)聽
- Therapy and counseling聽
- Patient education聽
- Care coordination聽
- Medication management聽
- Ordering and interpreting diagnostic tests and imaging聽
- Use or聽monitoring聽of Food and Drug Administration聽(FDA)-authorized devices聽
ACCESS is intended to be a supplemental approach to traditional care. Primary care physicians and specialists will be able to refer patients to ACCESS organizations and will receive regular electronic updates on patient progress.
New Options for Beneficiaries
Unlike most other Innovation Center models, beneficiaries will be able to voluntarily sign up directly with an ACCESS organization or receive a referral from a physician. CMS will maintain a public directory of ACCESS participants, including the conditions they treat and their risk-adjusted outcomes, to help providers and beneficiaries make informed choices based on their needs.
Chronic Condition Focused Clinical Tracks
ACCESS will launch with four clinical tracks, grouping related conditions with similar care approaches. Although CMS may add additional tracks and conditions in the future, the first four tracks address common chronic conditions among Medicare beneficiaries (affecting over two-thirds of Medicare beneficiaries).
- Early Cardio-Kidney-Metabolic (eCKM):聽Hypertension, dyslipidemia, obesity, prediabetes
Outcome measures:聽Control聽of聽or improvement in聽blood pressure聽(BP), lipids, weight, HbA1c聽 - Cardio-Kidney-Metabolic (CKM):聽Diabetes,聽chronic kidney disease聽(CKD),聽atherosclerotic聽cardiovascular聽disease聽(ASCVD)聽
- Outcome measures:聽Control or improvement in BP, lipids, weight, HbA1c; CKD/diabetes require eGFR聽(estimated聽glomerular聽filtration聽rate)聽and UACR聽(urine聽albumin-to-creatinine聽ratio)聽data submission聽
- Musculoskeletal (MSK):聽Chronic pain
Outcome measures:聽Improvement in pain intensity, interference, function (via validated聽patient-reported聽outcome聽measures聽[PROMs])聽 - Behavioral Health:聽Depression and/or anxiety
Outcome measures:聽Improvement in symptoms (Patient Health Questionnaire-9聽[PHQ-9],聽Generalized聽Anxiety聽Disorder-7聽[GAD-7]);聽submission of聽World Health Organization Disability Assessment Schedule 2.0聽(WHODAS 2.0)聽for overall function聽
Participant organizations must manage all qualifying conditions within their chosen track.
Payments
CMS will release more details in the forthcoming request for applications (RFA). The model will use two payment approaches:
- Outcomes-Aligned Payments (OAPs):聽Paid to ACCESS organizations聽that聽achieve聽desired clinical outcomes, support technology-enabled interventions,聽and net savings for Medicare. OAPs are expected to be聽recurring聽(likely聽monthly) payments
- 颁辞-尘补苍补驳别尘别苍迟听笔补测尘别苍迟蝉:听Referring clinicians will receive approximately $30 per service, plus a one-time $10 bonus, for onboarding beneficiaries
To promote access in underserved areas, CMS will apply a fixed adjustment to OAPs for rural patients in qualifying tracks.
FDA鈥檚 Complementary TEMPO Pilot
罢丑别&苍产蝉辫;贵顿础鈥檚&苍产蝉辫; (TEMPO) pilot will work collaboratively with the ACCESS model. Manufacturers of digital health devices that have yet to receive FDA authorization can apply to TEMPO for enforcement discretion, allowing their devices to be used by ACCESS participants for covered care. The FDA is seeking statements of interest for participation in the TEMPO pilot beginning in January 2026. The agency plans to select up to 10 manufacturers in each of four specific clinical use areas to participate in the pilot.
Next Steps
Interested applicants should begin exploring participation as a Medicare Part B-enrolled provider if they have yet to enroll. Other key considerations for Medicare organizations include:
- 聽a nonbinding letter of interest to聽the Innovation Center聽
- Evaluate readiness to deliver technology-enabled, outcomes-focused care聽
- Assess capacity to manage qualifying conditions across clinical tracks聽
- Plan for data collection, reporting, and performance measurement聽
- Consider partnerships with technology vendors and referring clinicians聽
- Monitor regulatory developments and payment聽methodology聽updates聽
How 红领巾瓜报 Can Help
红领巾瓜报聽can help organizations聽navigate the application process, develop implementation strategies, and position your organization for success in the evolving Medicare landscape.聽If your organization is considering聽participation in ACCESS or wants to understand how this model could聽affect聽your market,聽contact聽our experts below.



